B B Oven Ustaalioglu1, O Balvan2, A Bilici3, A Develi2, M Aliustaoglu2, F A Vardar4, B Erkol5. 1. Department of Medical Oncology, HaydarpasaNumuneEducation and Research Hospital, Selimiye Mah, Şair Nesimi sok, Kardeşler Apt., No: 1, Daire: 4, Uskudar, 34668, Istanbul, Turkey. basakoven@yahoo.com. 2. Department of Medical Oncology, Dr. LutfiKirdarKartal Education and Research Hospital, Istanbul, Turkey. 3. Department of Medical Oncology, Medipol University, Istanbul, Turkey. 4. Department of Pathology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey. 5. Department of Medical Oncology, HaydarpasaNumuneEducation and Research Hospital, Selimiye Mah, Şair Nesimi sok, Kardeşler Apt., No: 1, Daire: 4, Uskudar, 34668, Istanbul, Turkey.
Abstract
PURPOSE: In the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancer patients and also prognostic factors related with recurrence-free survival (RFS) in recurrent patients. PATIENTS/ METHODS: We evaluated retrospectively 1980 breast cancer patients. Relapsed was defined as early if it was occured first 5 year of follow-up (Group 1) and late if it was occured after 5 years (Group 2). The clinicopathological factors were compared in respect of time of recurrence. The prognostic factors were evaluated using univariate and multivariate analyses. RESULTS: Recurrence wase detected in 141 patient during follow-up. Tumors recurred after 5 years more likely to have lower stage (p = 0.05), tumors without lymphovascular invasion (LVI) (p < 0.001) and perineural invasion (PNI) (p = 0.01), and also HER2 negative (p < 0.001). The median RFS time and 5 years RFS rates were 42.9 months and 31.9 %, respectively. LVI (p = 0.01), PNI (p = 0.03), HER2 (p = 0.003), progesterone receptor (PR) (p = 0.04), the presence of neoadjuvant chemotherapy (p = 0.003), adjuvant hormonotherapy (p = 0.05) were found to be related with RFS. Axillary lymph node metastasis (p = 0.05) and the presence of PNI (p = 0.009) were poor prognostic factors for early recurrent group. PR-positive tumors (p = 0.001) and luminal subtypes (p = 0.03) had instances of late recurrences significantly. CONCLUSIONS: Clinicopathological factors predicting the recurrence time in breast cancer were important to modify adjuvant therapy.
PURPOSE: In the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancerpatients and also prognostic factors related with recurrence-free survival (RFS) in recurrent patients. PATIENTS/ METHODS: We evaluated retrospectively 1980 breast cancerpatients. Relapsed was defined as early if it was occured first 5 year of follow-up (Group 1) and late if it was occured after 5 years (Group 2). The clinicopathological factors were compared in respect of time of recurrence. The prognostic factors were evaluated using univariate and multivariate analyses. RESULTS: Recurrence wase detected in 141 patient during follow-up. Tumors recurred after 5 years more likely to have lower stage (p = 0.05), tumors without lymphovascular invasion (LVI) (p < 0.001) and perineural invasion (PNI) (p = 0.01), and also HER2 negative (p < 0.001). The median RFS time and 5 years RFS rates were 42.9 months and 31.9 %, respectively. LVI (p = 0.01), PNI (p = 0.03), HER2 (p = 0.003), progesterone receptor (PR) (p = 0.04), the presence of neoadjuvant chemotherapy (p = 0.003), adjuvant hormonotherapy (p = 0.05) were found to be related with RFS. Axillary lymph node metastasis (p = 0.05) and the presence of PNI (p = 0.009) were poor prognostic factors for early recurrent group. PR-positive tumors (p = 0.001) and luminal subtypes (p = 0.03) had instances of late recurrences significantly. CONCLUSIONS: Clinicopathological factors predicting the recurrence time in breast cancer were important to modify adjuvant therapy.
Entities:
Keywords:
Breast cancer; Late recurrence; Recurrence; Recurrence-free survival
Authors: Reshma Jagsi; Rita Abi Raad; Saveli Goldberg; Timothy Sullivan; James Michaelson; Simon N Powell; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-15 Impact factor: 7.038
Authors: Abenaa M Brewster; Gabriel N Hortobagyi; Kristine R Broglio; Shu-Wan Kau; Cesar A Santa-Maria; Banu Arun; Aman U Buzdar; Daniel J Booser; Vincente Valero; Melissa Bondy; Francisco J Esteva Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: Jaclyn L F Bosco; Timothy L Lash; Marianne N Prout; Diana S M Buist; Ann M Geiger; Reina Haque; Feifei Wei; Rebecca A Silliman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-10-20 Impact factor: 4.254
Authors: A P Nunes; C Liang; W J Gradishar; T Dalvi; J Lewis; N Jones; E Green; M Doherty; J D Seeger Journal: Curr Oncol Date: 2019-04-01 Impact factor: 3.677
Authors: Mahmood Faraz; Andreas Tellström; Christina Edwinsdotter Ardnor; Kjell Grankvist; Lukasz Huminiecki; Björn Tavelin; Roger Henriksson; Håkan Hedman; Ingrid Ljuslinder Journal: BMC Cancer Date: 2020-05-24 Impact factor: 4.430
Authors: Benjamin Ansa; Wonsuk Yoo; Mary Whitehead; Steven Coughlin; Selina Smith Journal: Int J Environ Res Public Health Date: 2015-12-23 Impact factor: 3.390
Authors: Giulia Missori; Francesco Serra; Giorgia Prestigiacomo; Andrea Aurelio Ricciardolo; Lucio Brugioni; Roberta Gelmini Journal: F1000Res Date: 2020-05-11